Streetbeat News

Stock Prices

CALT

Asahi Kasei Corporation has made a $1.1 billion offer to acquire Swedish pharmaceutical company Calliditas Therapeutics AB (NASDAQ:CALT). The deal, which offers 208 Swedish krona per share and 416 Swedish krona per ADS, has been unanimously recommended by the Calliditas board. This acquisition aims to enhance Asahi Kasei's global pharmaceutical growth strategy, particularly in the U.S. market, by leveraging Calliditas' lead product, Tarpeyo, for IgA nephropathy.

Portfolio Pulse from Vandana Singh

May 28, 2024 | 4:03 pm

EXK

FCX

PAAS

Shares of precious metals stocks are trading higher amid strength in gold and silver.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 4:02 pm

COST

In the past three months, 27 analysts have provided ratings for Costco Wholesale (NASDAQ:COST), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $787.96, reflecting a 5.14% rise from the previous average. Analysts have frequently updated their recommendations, with several raising their price targets. Costco's strong financial performance, including a 5.75% revenue growth rate and a net margin of 2.98%, supports these positive ratings.

Portfolio Pulse from Benzinga Insights

May 28, 2024 | 4:01 pm

PAYS

In the last three months, 9 analysts have published ratings on PaySign (NASDAQ:PAYS), with a mix of bullish and somewhat bullish sentiments. Analysts have set a 12-month average price target of $5.61, reflecting a 10.87% increase from the previous target. Key analysts have maintained or raised their ratings and price targets, indicating positive sentiment. PaySign has shown strong financial performance with notable revenue growth, net margin, ROE, and ROA, and maintains a balanced debt approach.

Portfolio Pulse from Benzinga Insights

May 28, 2024 | 4:01 pm

CRGX

CARGO Therapeutics shares are trading lower after the company announced a securities purchase agreement for a private investment in public equity financing, expected to result in gross proceeds of approximately $110.0 million.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 4:00 pm

LQDT

Liquidity Services (NASDAQ:LQDT) received 4 'Somewhat Bullish' ratings from analysts in the last quarter, with a consistent 12-month price target of $27.00. The company's financials show positive revenue growth, strong net margin, ROE, ROA, and prudent debt management.

Portfolio Pulse from Benzinga Insights

May 28, 2024 | 4:00 pm

APDN

CALT

GME

INSM

MRAI

NCPL

PEGY

U.S. stocks traded mixed with the Dow Jones falling over 100 points, while the NASDAQ and S&P 500 saw gains. GameStop shares spiked 24% after completing an equity offering. Insmed, Calliditas Therapeutics, and Pineapple Energy saw significant gains, while Applied DNA Sciences, Marpai, and Netcapital experienced sharp declines.

Portfolio Pulse from Avi Kapoor

May 28, 2024 | 4:00 pm

EPR

EPR Properties (NYSE:EPR) has received mixed analyst ratings over the past three months, with a recent trend towards more bearish sentiments. Analysts have lowered their price targets, reflecting concerns about the company's revenue decline and lower return on equity, despite strong net margins and effective debt management.

Portfolio Pulse from Benzinga Insights

May 28, 2024 | 4:00 pm

TMUS

USM

T-Mobile US, Inc. (NASDAQ: TMUS) announced it will acquire nearly all of UScellular's (NYSE: USM) wireless operations for approximately $4.4 billion. The acquisition will expand T-Mobile's network to millions of new customers, particularly in underserved rural areas. The deal will be financed with a combination of cash and up to $2 billion of debt. T-Mobile customers will benefit from enhanced network performance and coverage.

Portfolio Pulse from Dylan Berman

May 28, 2024 | 3:59 pm

NVO

Novo Nordisk (NYSE:NVO) is under scrutiny for the high prices of its diabetes and obesity drugs, Ozempic and Wegovy. The company retains about 60% of the list price after rebates and fees. Senator Bernie Sanders is urging price reductions, highlighting the disparity between production costs and market prices. Novo Nordisk defends its pricing, citing significant investment in drug development. The potential market for GLP-1 drugs could reach $150 billion by the early 2030s.

Portfolio Pulse from Vandana Singh

May 28, 2024 | 3:59 pm